Steven Mah
Stock Analyst at TD Cowen
(2.17)
# 2,872
Out of 5,008 analysts
29
Total ratings
37.04%
Success rate
10.63%
Average return
Main Sectors:
Stocks Rated by Steven Mah
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| TWST Twist Bioscience | Reiterates: Buy | $58 | $31.85 | +82.10% | 3 | Nov 26, 2024 | |
| BLFS BioLife Solutions | Maintains: Buy | $28 → $31 | $26.52 | +16.89% | 2 | Nov 13, 2024 | |
| DNA Ginkgo Bioworks Holdings | Maintains: Outperform | $280 → $120 | $14.87 | +706.99% | 2 | Mar 1, 2024 | |
| RXRX Recursion Pharmaceuticals | Initiates: Market Perform | n/a | $5.53 | - | 1 | Jan 26, 2024 | |
| SDGR Schrödinger | Initiates: Outperform | $42 | $21.29 | +97.28% | 1 | Jan 26, 2024 | |
| ABCL AbCellera Biologics | Initiates: Outperform | n/a | $5.87 | - | 1 | Feb 28, 2023 | |
| OABI OmniAb | Initiates: Outperform | $10 | $1.68 | +495.24% | 1 | Feb 22, 2023 | |
| ABSI Absci | Upgrades: Outperform | n/a | $3.76 | - | 1 | Aug 12, 2022 | |
| CDXS Codexis | Maintains: Outperform | $39 → $21 | $2.69 | +680.67% | 2 | Jul 15, 2022 | |
| NTRA Natera | Maintains: Overweight | $150 → $155 | $170.38 | -9.03% | 4 | Jul 6, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $135 → $140 | $23.01 | +508.43% | 3 | Mar 5, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $20 → $52 | $1.52 | +3,321.05% | 3 | Feb 11, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $340 → $415 | $101.02 | +310.81% | 4 | Dec 22, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $168 → $250 | $29.60 | +744.59% | 1 | Jul 8, 2020 |
Twist Bioscience
Nov 26, 2024
Reiterates: Buy
Price Target: $58
Current: $31.85
Upside: +82.10%
BioLife Solutions
Nov 13, 2024
Maintains: Buy
Price Target: $28 → $31
Current: $26.52
Upside: +16.89%
Ginkgo Bioworks Holdings
Mar 1, 2024
Maintains: Outperform
Price Target: $280 → $120
Current: $14.87
Upside: +706.99%
Recursion Pharmaceuticals
Jan 26, 2024
Initiates: Market Perform
Price Target: n/a
Current: $5.53
Upside: -
Schrödinger
Jan 26, 2024
Initiates: Outperform
Price Target: $42
Current: $21.29
Upside: +97.28%
AbCellera Biologics
Feb 28, 2023
Initiates: Outperform
Price Target: n/a
Current: $5.87
Upside: -
OmniAb
Feb 22, 2023
Initiates: Outperform
Price Target: $10
Current: $1.68
Upside: +495.24%
Absci
Aug 12, 2022
Upgrades: Outperform
Price Target: n/a
Current: $3.76
Upside: -
Codexis
Jul 15, 2022
Maintains: Outperform
Price Target: $39 → $21
Current: $2.69
Upside: +680.67%
Natera
Jul 6, 2021
Maintains: Overweight
Price Target: $150 → $155
Current: $170.38
Upside: -9.03%
Mar 5, 2021
Maintains: Overweight
Price Target: $135 → $140
Current: $23.01
Upside: +508.43%
Feb 11, 2021
Upgrades: Overweight
Price Target: $20 → $52
Current: $1.52
Upside: +3,321.05%
Dec 22, 2020
Upgrades: Overweight
Price Target: $340 → $415
Current: $101.02
Upside: +310.81%
Jul 8, 2020
Maintains: Overweight
Price Target: $168 → $250
Current: $29.60
Upside: +744.59%